Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· January 30, 2026

Catalyst Watch: Amazon earnings, IPO blitz, gold swings, and the jobs report

View original at seekingalpha.com
Catalyst Watch: Amazon earnings, IPO blitz, gold swings, and the jobs report [bad day at wall street] franckreporter Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Economists expect 65K job additions for the month and for the unemployment rate to remain at 4.4%

    80% confidence

  • Options trading implies double-digit swings for Reddit, Gold.com, and Roblox after they report

    80% confidence

  • Key suppliers Celsius Holdings and McCormick trade directionally with PepsiCo about 75% of the time after earnings

    80% confidence

  • Suppliers that have a high trading correlation with Amazon on earnings day include Hamilton Beach, Marvell Technology, and Aterian

    80% confidence

  • Traders expect more outsized swings for spot gold and silver

    80% confidence

  • Semrush traded at less than 1% from the deal price at the time of publication

    80% confidence

  • Coinbase Global and Reddit are set up for a volatile week of trading based on options volume

    80% confidence

  • Options trading implies a double-digit swing in share price for Galaxy Digital and fuboTV after they report

    80% confidence

  • The Mag 7 are no longer trading as a unified group

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com